Floatz logo

TCR .ALPHA..BETA. (RECEPTOR), ANTI-(HUMAN P53 (PROTEIN)) (SYNTHETIC HUMAN SINGLE-CHAIN PRECURSOR) FUSION PROTEIN WITH INTERLEUKIN 2 (HUMAN)

Type 2 Diabetes

Altimmune, Inc.protein_peptidePhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

141 Active assets in the Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

TCR .ALPHA..BETA. (RECEPTOR), ANTI-(HUMAN P53 (PROTEIN)) (SYNTHETIC HUMAN SINGLE-CHAIN PRECURSOR) FUSION PROTEIN WITH INTERLEUKIN 2 (HUMAN) is also rated in:

obesity disorderDormant
CCC
Indicative ·
53 / 100
View asset →
bladder transitional cell carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
urethra cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →